Listen on the go
CORRECT!
Next question
touchONCOLOGY touchONCOLOGY
Prostate Cancer
Watch Time: 7 mins

Arnulf Stenzl: Highlights from EAU23!

Copy Link
Published Online: May 25th 2023

touchONCOLOGY caught up with the Secretary General of the European Association of Urology (EAU), Prof Arnulf Stenzl, to discuss some of the key advances from the conference. He focusses this interview on prostate cancer, early detection, systemic therapy, new therapies in castration-resistant prostate cancer and the latest knowledge in the use of PARP inhibitors.

Topics covered

  • Improving early detection of prostate cancer, postate specific antigen and new imaging techniques (00:20)
  • Developments in systemic therapy of early, hormone sensitive metastatic prostate cancer, including the ARCHES trial data (3:30)
  • New therapies for castration-resistant prostate cancer (5:45)
  • Latest advances and knowledge of PARP inhibitors (6:45)

Disclosures: Arnulf Stenzl has nothing to disclose in relation to this video interview.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.

Filmed as a highlight of EAU23

Access more content on genitourinary cancers here 

 

Share this Video
Related Videos In Prostate Cancer
Prostate Cancer
Developed by Touch
Arnulf Stenzl: Highlights from EAU23!
Watch Time: 7 mins

touchONCOLOGY caught up with the Secretary General of the European Association of Urology (EAU), Prof Arnulf Stenzl, to discuss some of the key advances from the conference. He focusses this interview on prostate cancer, early detection, systemic therapy, new therapies in castration-resistant prostate cancer and the latest knowledge in the use of PARP inhibitors. Topics […]

Genitourinary Cancer, Prostate Cancer
Axel Merseburger: Current advances in prostate cancer treatment options and what we might expect in the next 5 years
Watch Time: 3 mins

Our Editor-in-Chief Axel Merseburger (Lübeck University, Lübeck, Germany) discusses the most important recent advances in the treatment landscape for prostate cancer, including screening using MRI and PSMA PET-CT scans, and triplet therapies using hormone therapy and PARP inhibitors. He also takes a look to the future, discussing developments he hopes to see in early detection, […]

Genitourinary Cancer, Prostate Cancer
Developed by Touch
Axel Merseburger: Highlights of EAU23
Watch Time: 5 mins

Our Editor-in-Chief Axel Merseburger (Lübeck University, Lübeck, Germany) discusses key data from this year’s European Association of Urology annual meeting (EAU23) in the field of prostate cancer. He discusses results from the LuTectomy trial, the 15-year update of the ProtecT trial and the PROBASE trial. Question: Please summarize the most important presentations and data from […]

Trending In Prostate Cancer:

Arnulf Stenzl: Highlights from EAU23!
Prostate Cancer
    • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72